|Bid||7.67 x 3000|
|Ask||8.03 x 28000|
|Day's range||7.15 - 8.52|
|52-week range||4.52 - 38.50|
|Beta (5Y monthly)||2.50|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...